173 related articles for article (PubMed ID: 32158196)
21. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors.
Bruin MAC; de Vries N; Lucas L; Rosing H; Huitema ADR; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Feb; 1138():121925. PubMed ID: 31915109
[TBL] [Abstract][Full Text] [Related]
22. Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry.
Darwish HW; Kadi AA; Attwa MW; Almutairi HS
Clin Chim Acta; 2018 May; 480():180-185. PubMed ID: 29458050
[TBL] [Abstract][Full Text] [Related]
23. A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate.
Attwa MW; Kadi AA; Darwish HW; Amer SM; Alrabiah H
Eur J Mass Spectrom (Chichester); 2018 Aug; 24(4):344-351. PubMed ID: 29629565
[TBL] [Abstract][Full Text] [Related]
24. LC-MS/MS method for the determination of clodronate in human plasma.
Hasan M; Schumacher G; Seekamp A; Taedken T; Siegmund W; Oswald S
J Pharm Biomed Anal; 2014 Nov; 100():341-347. PubMed ID: 25194348
[TBL] [Abstract][Full Text] [Related]
25. A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment.
Alrabiah H; Kadi AA; Attwa MW; Abdelhameed AS
RSC Adv; 2019 Feb; 9(9):4862-4869. PubMed ID: 35514667
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma.
Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():121-5. PubMed ID: 24145016
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.
Mooiman KD; Maas-Bakker RF; Rosing H; Beijnen JH; Schellens JH; Meijerman I
Biomed Chromatogr; 2013 Sep; 27(9):1107-16. PubMed ID: 23674377
[TBL] [Abstract][Full Text] [Related]
28. Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products.
Thummar M; Kuswah BS; Samanthula G; Bulbake U; Gour J; Khan W
J Pharm Biomed Anal; 2018 Oct; 160():89-98. PubMed ID: 30075398
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry.
Wiegand R; Wu J; Sha X; LoRusso P; Li J
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Feb; 878(3-4):333-9. PubMed ID: 20005184
[TBL] [Abstract][Full Text] [Related]
30. Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation.
Amer SM; Kadi AA; Darwish HW; Attwa MW
Chem Cent J; 2017 May; 11(1):45. PubMed ID: 29086823
[TBL] [Abstract][Full Text] [Related]
31. A semi-automated LC-MS/MS method for the determination of LCI699, a steroid 11β-hydroxylase inhibitor, in human plasma.
Li W; Luo S; Rebello S; Flarakos J; Tse FL
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():182-93. PubMed ID: 24814004
[TBL] [Abstract][Full Text] [Related]
32. In vitro metabolic stability and metabolite profiling of TJ0711 hydrochloride, a newly developed vasodilatory β-blocker, using a liquid chromatography-tandem mass spectrometry method.
Huang J; Si L; Fan Z; Hu L; Qiu J; Li G
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(30):3386-92. PubMed ID: 21963275
[TBL] [Abstract][Full Text] [Related]
33. A highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study.
Kadi AA; Abdelhameed AS; Darwish HW; Attwa MW; Al-Shakliah NS
Biomed Chromatogr; 2016 Aug; 30(8):1248-55. PubMed ID: 26683307
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a high-performance liquid chromatography method for the quantification of talazoparib in rat plasma: Application to plasma protein binding studies.
Hidau MK; Kolluru S; Palakurthi S
Biomed Chromatogr; 2018 Feb; 32(2):. PubMed ID: 28677821
[TBL] [Abstract][Full Text] [Related]
35. LC-MS/TOF and UHPLC-MS/MS study of in vivo fate of rifamycin isonicotinyl hydrazone formed on oral co-administration of rifampicin and isoniazid.
Prasad B; Singh S
J Pharm Biomed Anal; 2010 Jul; 52(3):377-83. PubMed ID: 19692195
[TBL] [Abstract][Full Text] [Related]
36. Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadruple time-of-flight mass spectrometry and in-silico prediction.
Nassar AE; Adams PE
Curr Drug Metab; 2003 Aug; 4(4):259-71. PubMed ID: 12871044
[TBL] [Abstract][Full Text] [Related]
37. Plasma pharmacokinetics and tissue distribution study of cajaninstilbene acid in rats by liquid chromatography with tandem mass spectrometry.
Hua X; Fu YJ; Zu YG; Wu N; Kong Y; Li J; Peng X; Efferth T
J Pharm Biomed Anal; 2010 Jun; 52(2):273-9. PubMed ID: 20116956
[TBL] [Abstract][Full Text] [Related]
38. Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability.
Kadi AA; Darwish HW; Attwa MW; Amer SM
PLoS One; 2016; 11(10):e0164967. PubMed ID: 27764191
[TBL] [Abstract][Full Text] [Related]
39. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
[TBL] [Abstract][Full Text] [Related]
40. Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.
Midde NM; Rahman MA; Rathi C; Li J; Meibohm B; Li W; Kumar S
PLoS One; 2016; 11(2):e0149225. PubMed ID: 26872388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
